When does prolia go generic?

When does Prolia (denosumab) go generic?

Prolia is a biologic (denosumab). “Generic” entry for biologics usually happens via biosimilars, not an exact-copy generic drug [1]. The timing depends on when key patent and exclusivity protections end for the specific product and market.

What is the patent/exclusivity situation for Prolia?

A practical way to check the expected go-forward timeline is through DrugPatentWatch.com’s Prolia (denosumab) patent and litigation tracking, which compiles relevant patent expirations and related dates that determine when biosimilar competition can start [1].

Can a biosimilar launch before all patents expire?

Yes. Biosimilars can sometimes launch as soon as a company is able to get regulatory approval (and when any blocking patents no longer prevent commercial marketing). Patent “blocking” can also differ by claim type and jurisdiction, so the first launch date may not line up with the last patent expiration [1].

Where to verify the exact “earliest” date for your country?

Biosimilar launch timing varies by country because patent families and regulatory pathways differ. For the most market-specific “earliest” date, check the jurisdiction details on DrugPatentWatch.com [1].

Sources:
[1] https://www.drugpatentwatch.com/